Taysha Gene Therapies (TSHA) Common Equity (2019 - 2026)
Taysha Gene Therapies (TSHA) posted Common Equity of $211.9 million for Q1 2026, down 14.17% sequentially from $246.9 million in Q4 2025, and up 284.94% YoY from $55.1 million in Q1 2025.
Taysha Gene Therapies (TSHA) Common Equity (2019 - 2026) Analysis & Trends
Taysha Gene Therapies has reported Common Equity for 8 years, with the latest figure at $211.9 million in Q1 2026.
- Quarterly Common Equity rose 284.94% year-over-year to $211.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $211.9 million (up 284.94% YoY) and the FY2025 annual result came in at $246.9 million, up 245.25% from the prior year.
- Common Equity eased to $211.9 million in Q1 2026 per TSHA's latest filing, from $246.9 million in the prior quarter.
- Over five years, Common Equity peaked at $248.7 million in Q2 2025 and troughed at -$49.1 million in Q3 2023.
- A 5-year average of $80.8 million and a median of $55.1 million in 2025 frame the typical range for Common Equity.
- The widest YoY moves for Common Equity: up 7796.42% in 2023, down 558.88% in 2023.
- Over 5 years, Common Equity stood at $949000.0 in 2022, then surged by 7796.42% to $74.9 million in 2023, then decreased by 4.55% to $71.5 million in 2024, then surged by 245.25% to $246.9 million in 2025, then fell by 14.17% to $211.9 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $211.9 million, $246.9 million, and $219.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Taysha Gene Therapies | 1.94 Bn | 1.94 Bn | - | 387.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 387.27 Mn |
| Mar 31, 2026 | 211.94 Mn |
| Dec 31, 2025 | 246.94 Mn |
| Sep 30, 2025 | 218.99 Mn |
| Jun 30, 2025 | 248.73 Mn |
| Mar 31, 2025 | 55.06 Mn |
| Dec 31, 2024 | 71.53 Mn |
| Sep 30, 2024 | 88.80 Mn |
| Jun 30, 2024 | 108.87 Mn |
| Mar 31, 2024 | 53.85 Mn |
| Dec 31, 2023 | 74.94 Mn |
| Sep 30, 2023 | -49.11 Mn |
| Jun 30, 2023 | -37.11 Mn |
| Mar 31, 2023 | -14.95 Mn |
| Dec 31, 2022 | 949,000.00 |
| Sep 30, 2022 | 10.70 Mn |
| Jun 30, 2022 | 32.51 Mn |
| Mar 31, 2022 | 50.74 Mn |
| Dec 31, 2021 | 95.38 Mn |
| Sep 30, 2021 | 140.39 Mn |